BR9815913A - Cepa viral de hepatite b humana mutante e seususos - Google Patents

Cepa viral de hepatite b humana mutante e seususos

Info

Publication number
BR9815913A
BR9815913A BR9815913-5A BR9815913A BR9815913A BR 9815913 A BR9815913 A BR 9815913A BR 9815913 A BR9815913 A BR 9815913A BR 9815913 A BR9815913 A BR 9815913A
Authority
BR
Brazil
Prior art keywords
present
provides
virus
nucleic acid
hepatitis
Prior art date
Application number
BR9815913-5A
Other languages
English (en)
Inventor
Chong Jin Oon
Yi Zhao
Wei Ning Chen
Gek Keow Lim
Original Assignee
Government Of The Republic Of Singapore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Government Of The Republic Of Singapore filed Critical Government Of The Republic Of Singapore
Publication of BR9815913A publication Critical patent/BR9815913A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00Reverse transcribing DNA viruses
    • C12N2730/00011Details
    • C12N2730/10011Hepadnaviridae
    • C12N2730/10111Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

"CEPA VIRAL DE HEPATITE B HUMANA MUTANTE E SEUSUSOS". A presente invenção fornece uma cepa isolada de vírusda Hepatite B designada Cepa Oon 'S'-133-Antigeno Superficial deVirus da Hepatite B Humana (Metionina para Treonina) cujogenona viral constituinte é depositado sob os Nos. de AcessãoP97121501, P97121502 e P97121503 na European Collection ofCell Culture em 15 de dezembro de 1997. A presente invençãotambém provê um ácido nucléico isolado codificando umpolipeptideo que é um antigeno superficial principal, mutante, deuma cepa do vírus de hepatite B, tal polipeptideo tendo umaseq³ência de aminoácidos que difere da seq³ência deaminoácidos de um antígeno superficial principal de um vírus dehepatite B do tipo selvagem em que o aminoácido na posiçãonumero 133 do referido polipeptídeo é uma treonina em vez deuma metionina. A presente invenção provê também um ácidonucléico isolado que codifica um peptídeo, onde o peptídeo écodificado por uma molécula de ácido nucléico compreendendonucleotídeos 527 até 595 da SEQ. ID. NO. 1, e o peptídeopurificado. A presente invenção também provê vários métodos deutilizar os peptídeos e ácidos nucléicos isolados, revelados. Apresente invenção também provê vários usos do ácido nucléicoisolado, revelado, polipeptídeos e peptídeos, e anticorpos.
BR9815913-5A 1998-06-19 1998-06-19 Cepa viral de hepatite b humana mutante e seususos BR9815913A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/SG1998/000046 WO1999066048A1 (en) 1998-06-19 1998-06-19 A mutant human hepatitis b viral strain and uses thereof

Publications (1)

Publication Number Publication Date
BR9815913A true BR9815913A (pt) 2001-12-26

Family

ID=20429862

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9815913-5A BR9815913A (pt) 1998-06-19 1998-06-19 Cepa viral de hepatite b humana mutante e seususos

Country Status (22)

Country Link
US (1) US6558675B1 (pt)
EP (1) EP1098981A1 (pt)
JP (1) JP2002518014A (pt)
KR (1) KR100498118B1 (pt)
CN (1) CN1322251A (pt)
AR (1) AR020093A1 (pt)
AU (1) AU756866B2 (pt)
BG (1) BG105066A (pt)
BR (1) BR9815913A (pt)
CA (1) CA2330935C (pt)
HU (1) HUP0103409A3 (pt)
IL (1) IL140364A0 (pt)
IS (1) IS5778A (pt)
MX (1) MXPA00012720A (pt)
MY (1) MY118955A (pt)
NO (1) NO20006456L (pt)
NZ (1) NZ508890A (pt)
PL (1) PL192129B1 (pt)
TR (1) TR200003777T2 (pt)
UA (1) UA73476C2 (pt)
WO (1) WO1999066048A1 (pt)
YU (1) YU80600A (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200643171A (en) 2005-06-07 2006-12-16 Temasek Life Sciences Lab Ltd Porcine circovirus type 2 vaccines
JP7398556B2 (ja) 2019-09-30 2023-12-14 ギリアード サイエンシーズ, インコーポレイテッド Hbvワクチン及びhbvを治療する方法
CN113201051B (zh) * 2021-04-27 2022-08-02 复旦大学 一种乙肝病毒表面蛋白突变体及其在抗乙肝病毒中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9401987D0 (en) * 1994-02-02 1994-03-30 Imperial College Modified nucleic acid
WO1998011916A1 (en) * 1996-09-18 1998-03-26 The Board Of Regents Of The University Of Texas System Viral defective interfering particles and uses thereof

Also Published As

Publication number Publication date
NO20006456L (no) 2001-02-16
WO1999066048A1 (en) 1999-12-23
CA2330935A1 (en) 1999-12-23
CN1322251A (zh) 2001-11-14
HUP0103409A3 (en) 2003-10-28
NZ508890A (en) 2004-04-30
PL345573A1 (en) 2001-12-17
NO20006456D0 (no) 2000-12-18
YU80600A (sh) 2005-06-10
AR020093A1 (es) 2002-04-10
MY118955A (en) 2005-02-28
HUP0103409A2 (hu) 2001-12-28
TR200003777T2 (tr) 2001-06-21
MXPA00012720A (es) 2002-05-08
UA73476C2 (en) 2005-08-15
PL192129B1 (pl) 2006-09-29
US6558675B1 (en) 2003-05-06
AU7795198A (en) 2000-01-05
JP2002518014A (ja) 2002-06-25
CA2330935C (en) 2005-05-10
KR20010106129A (ko) 2001-11-29
KR100498118B1 (ko) 2005-07-01
EP1098981A1 (en) 2001-05-16
AU756866B2 (en) 2003-01-23
BG105066A (en) 2001-09-28
IS5778A (is) 2000-12-19
IL140364A0 (en) 2002-02-10

Similar Documents

Publication Publication Date Title
Morris et al. Isolation and characterization of human calcitonin gene-related peptide
Takeya et al. DNA sequence of the viral and cellular src gene of chickens. 1. Complete nucleotide sequence of an EcoRI fragment of recovered avian sarcoma virus which codes for gp37 and pp60src
Bellisario et al. Human chorionic gonadotropin: linear amino acid sequence of the α subunit
Speck et al. An Epstein-Barr virus transcript from a latently infected, growth-transformed B-cell line encodes a highly repetitive polypeptide.
JP2612854B2 (ja) 共有結合した細胞調節ポリペプチド
Bergmann et al. The JHM strain of mouse hepatitis virus induces a spike protein-specific Db-restricted cytotoxic T cell response
DK1218751T3 (da) Cöliakidiagnose under anvendelse af et gliadinepitop
KR960704038A (ko) 세포 표면 수용체 Hek와 결합하는 사이토킨(Cytokines That Bind the Cell Surface Receptor Hek)
CY1105680T1 (el) Μολυσματικος κλωνος cdna βορειοαμερικανικου ιου χοιρειου αναπαραγωγικου και αναπνευστικου συνδρομου (prrs) και χρησεις αυτου
KR870009025A (ko) 재조합 숙주로부터 제조한 아프로티닌 동족체, 그의 방법, 표현 벡타 및 재조합 숙주 및 그의 재약상 용도
Geschwind et al. The Structure of the β-Melanocyte-stimulating Hormone
Mishiro et al. An autoantibody cross-reactive to hepatitis C virus core and a host nuclear antigen
BR9815912A (pt) Cepa viral de hepatite b induzida por vacina e seus usos
DK0644894T3 (da) Peptid til stimulering af Hepatitis C virus-specifikke cytotoksiske T-lymfocytter
Chatterjee et al. Homology of adenoviral E3 glycoprotein with HLA-DR heavy chain.
Huang et al. Respiratory syncytial virus mRNA coding assignments
Antón et al. A transmissible gastroenteritis coronavirus nucleoprotein epitope elicits T helper cells that collaborate in the in vitro antibody synthesis to the three major structural viral proteins
Baron et al. Antibodies against a synthetic peptide of the poliovirus replicase protein: reaction with native, virus-encoded proteins and inhibition of virus-specific polymerase activities in vitro
BR9815913A (pt) Cepa viral de hepatite b humana mutante e seususos
DE69935599D1 (de) Modifizierte hcv peptid-impfstoffe
NO20005081L (no) Et polypeptid som omfatter aminosyren fra et N-terminalt kolinbindende protein A trunkat, vaksine avledet derav og anvendelser derav
WO1999020761A3 (en) Compositions and methods for identifying and testing therapeutics against hsv infection
BRPI0407399A (pt) molécula, vetor recombinante, polipeptìdeo purificado, anticorpos purificados, célula hospedeira, métodos para produzir um polipeptìdeo, para detectar uma racemase codificada por um suqüência de nucleotìdeos, para tratar uma molécula, para detectar um d-aminoácido e para detectar atividade racemase em um meio de reação, complexo imunológico, kit, composição imunizante, e, plataforma tecnológica e todos os reagentes e dispositivos
Okasinski et al. Analysis of intracellular feline leukemia virus proteins II. Generation of feline leukemia virus structural proteins from precursor polypeptides
Iwakura et al. Presence of a common structure in the two molecular species of mouse L cell interferon

Legal Events

Date Code Title Description
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: DE ACORDO COM O ART 36 DA LPI (LEI 9.279/96) 2O, O PEDIDO VOLTA A EXAME SENDO CONSIDERADO NAO PATENTEAVEL PELAS RAZOES EXPOSTAS NO PARECER TECNICO ANTERIOR.